Malaria remains one of the world's most frequent causes of mortality and morbidity, with between 200 and 300 million cases and over two million deaths per year (18) . With the recent spread of resistance to commonly used antimalarials, such as chloroquine and pyrimethamine, there is an urgent need for new therapeutic compounds. Aminooxy compounds (or O-hydroxylamines) have been known for some time as potent inhibitors of pyridoxal-5-phosphate-dependent enzymes, such as aminotransferases, serine hydroxymethyltransferase, tyrosine decarboxylase, cystathionase, and ornithine decarboxylase, whereby the aminooxy moiety forms a stable oxime with the aldehyde group present on the cofactor (1, 2, 10, 11, 19) . One compound in particular, canaline (the aminooxy analogue of ornithine), has been well studied as an antimetabolite generated from canavanine (the guanidinooxy analogue of arginine) present in legumes (13) . Despite the demonstrated potential of canaline for inhibiting ornithine aminotransferase and ornithine decarboxylase (4, 10, 12, 17) , fairly large doses of the compound are required in order to see substantial mammalian toxicity (4) . In this context, canaline has been examined as an anticancer agent based on disrupting polyamine synthesis and other biochemical processes in tumor cells (10) . As most parasites and bacteria are rapidly growing organisms with a concomitant requirement for polyamine biosynthesis (8) , these organisms are susceptible to compounds which interfere with the relevant pathways. In the present study, a series of aminooxy compounds, including canaline, have been tested as antimalarial agents in vitro and several have been discovered to have potent activity.
Plasmodium falciparum clone 3D7 (chloroquine and pyrimethamine sensitive) was cultured in Aϩ human erythrocytes at 5% hematocrit by the method of Trager and Jensen (16) with a medium consisting of RPMI 1640 (pH 7.4) plus 2 g of glucose per liter, 1 g of sodium bicarbonate per liter, 5 g of Albumax II (Gibco, Paisley, United Kingdom) per liter, and 26 mg of hypoxanthine per liter. To examine the antimalarial properties of test compounds, stock solutions of a given drug were serially diluted 10-fold from 10 mM down to 10 nM, and 10 l of each dilution was added to the appropriate wells of a 96-well microtiter plate. Infected blood was diluted to a hematocrit of 1.5% and a parasitemia of 3 to 5%, and then 90 l was added to the microtiter wells. The plate was then incu-bated at 37°C in a candle jar for 48 h. After incubation, each well was resuspended, a thin smear was made and stained with Diff-Quik (Dade Behring, Milton Keynes, United Kingdom), and then at least 1,000 erythrocytes were counted per slide. The resulting parasitemia for each drug dilution was used in the Scientist computer program (MicroMath, Salt Lake City, Utah) and subjected to nonlinear fitting to a four-parameter equation to determine the 50% inhibitory concentration (IC 50 ). For synergism studies, two compounds were mixed at fixed ratios of their individual IC 50 s for P. falciparum 3D7 and then serially diluted and used as described above. The partial IC 50 s calculated from the mixtures were then used in the construction of an isobologram.
Canaline was obtained from Sigma (Poole, United King-
and methoxyamine were obtained from Aldrich (Poole, United Kingdom); phenyl-O-hydroxylamine was obtained from Fluka (Poole, United Kingdom); aminooxyphenylpropionate was obtained from Toronto Research Chemicals (North York, Ontario, Canada); benzyl-O-hydroxylamine was obtained from Acros (Loughborough, United Kingdom); and the CGP compounds were obtained from Novartis Pharma SA (Basel, Switzerland). All compounds were resuspended in either 100 mM HEPES (pH 7.4) or dimethyl sulfoxide.
The commercially available aminooxy compounds were tested over a final concentration range of 1 nM to 1 mM to determine their ability to inhibit the growth of P. falciparum in vitro (Table 1) . Of the 15 compounds examined, six were found to have IC 50 s lower than 10 M: allyl-O-hydroxylamine, phenyl-O-hydroxylamine, ethoxyamine, canaline, carboxymethoxylamine, and trimethylsilyl-O-hydroxylamine. Only canaline had a submicromolar IC 50 (297 Ϯ 23.6 nM). A series of eight proprietary aminooxy compounds were also made available by Novartis Pharma (Table 2 ). Of these, only CGP54382A and CGP51905A had IC 50 s lower than 10 M. However, CGP51905A, with an IC 50 of 242.1 Ϯ 18.8 nM, was found to be as potent as canaline.
Canaline is a known inhibitor of mammalian ornithine aminotransferase (4); we have found that it also inhibits malarial ornithine aminotransferase (unpublished data) and parasite aspartate aminotransferases involved in methionine regeneration from methylthioadenosine (3, 7; unpublished data). As interference with this methionine recycling pathway is known to be lethal for malaria organisms (9, 15) and ornithine ami-notransferase plays a key role in regulating ornithine levels (5, 14) , canaline was screened in combination with the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) in order to assess the possibility of therapeutic synergism. As seen in Fig. 1 , the isobologram for canaline plus ornithine is clearly synergistic.
It is possible to draw some broad structure-activity conclusions from the compounds used in the study. Introduction of an extra methyl group to phenyl-O-hydroxylamine (resulting in benzyl-O-hydroxylamine) led to a 10-fold loss of activity. However, addition of a nitro group to the ring of benzyl-O-hydroxylamine, the substitution of the ring hydrogens for fluorine, or the addition of two extra phenyl groups to the methyl linker had only a minor effect on antimalarial activity, with activity increasing twofold or less. Replacement of the central carbon in t-butyl-O-hydroxylamine with a silicon atom led to a 200-fold increase in activity. Lengthening the side chain of CGP51905A by one carbon led to an 80-fold loss of antimalarial activity, while the stereoisomers CGP54381A and CGP54382A had a fourfold difference in activity. While both canaline and aminooxyphenylpropionate are aminooxy analogues of physiological amino acids (ornithine and phenylalanine, respectively), there was a 150-fold difference in antimalarial activity. This 
a Inhibitors were screened in vitro against P. falciparum 3D7 over a final concentration range of 1 nM to 1 mM, as described in the text. VOL. 44, 2000 NOTES 2541 wide variance may be due to a number of different factors. First, aminooxyphenylpropionate contains a substitution in the ␣ position, whereas canaline contains a substitution in the ␥ position, which may make a large difference in the interaction of the inhibitor with the pyridoxal-5-phosphate of the target enzyme(s). Second, there may be a large difference in the ability of malaria organisms to transport the two compounds. However, the uptake of phenylalanine and ornithine in Plasmodium has not been well characterized. The effect of aminooxy substitution on the rate of uptake of a given amino acid is also completely unknown. As canaline has been shown to inhibit a number of diverse pyridoxal-5-phosphate-dependent enzymes and can also form stable oximes with ␣-keto acids important as biochemical intermediates (such as ␣-ketoglutarate) (6, 10, 13), it is not yet possible to define a single target as the mechanism of antimalarial activity. Nevertheless, the fact that canaline and DFMO are synergistic suggests that the inhibition of polyamine synthesis may play an important role in the action of the aminooxy compound. Since the IC 50 of canaline for human MIAPaCa-2 pancreatic carcinoma cells is 600 M and intraperitoneal injections of 500 mg of canaline/kg of body weight had no obvious toxic effects on rats (aside from sedation) (4, 10), malaria parasites appear to be approximately 2,000 times more susceptible to canaline. In vivo studies, with and without DFMO, are the next logical step in further investigating this class of compound. CGP55573A (Ͼ1 mM) a Inhibitors were tested in vitro against P. falciparum 3D7 over a final concentration range of 1 nM to 1 mM, as described in the text.
